Psychotherapy and Psychosomatics
March 18, 2019
Kurt Stocker, G. Hasler, Matthias Hartmann
5 “I kind of enjoyed the next few hours till dinner. I was still kind of floating on air” (5: 06) (T29). 6 “I had this awkward weight that I carried around me wherever I went (0: 47) ... Literally I had the sensation of this steal armor that I wore my entire life [that] – chunks of it – were falling off (3: 03)” (T16). 7 “I did immediately following the first session – and in the second and in...
Journal of Psychoactive Drugs
March 15, 2019
Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al.
207 citations
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...
Proceedings of the National Academy of Sciences
March 13, 2019
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart et al.
153 citations
Significance Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant. In contrast, a single subanesthetic dose of ketamine exerts rapid (within hours) and sustained antidepressant actions. Preclinical studies indicate that the ketamine metabolite ( 2R , 6R )-hydroxynorketamine [(...
Journal of Clinical Psychopharmacology
March 1, 2019
Kelly A. Bryant, Murat Altinay, Nora Finnegan et al.
Abstract Purpose There is an immediate need for more sustainable, effective therapies for treatment-resistant depression in patients who do not respond to traditional psychopharmacology. The aim of this study was to determine the efficacy and safety of intravenous ketamine infusions on the elderly population by using a case series of 6 geriatric patients with treatment-resistant depression....
JAMA Psychiatry
March 1, 2019
Gihyun Yoon, Ismene L. Petrakis, John H. Krystal
152 citations
This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.
Neuron
March 1, 2019
John H. Krystal, Chadi G. Abdallah, Gerard Sanacora et al.
443 citations
Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy. The rapid, profound, and sustainable antidepressant effects of ketamine...
Mental Health Weekly
February 25, 2019
Valerie A. Canady
A Food and Drug Administration (FDA) advisory committee earlier this month recommended the approval of a ketamine nasal spray treatment for adults with treatment‐resistant depression. Recent research has shown that ketamine treatment is gaining traction as an effective treatment for people struggling with depression.
Proceedings of the National Academy of Sciences
February 22, 2019
E. Lumsden, Timothy A. Troppoli, S. J. Myers et al.
159 citations
Significance Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that...
Neuropsychopharmacology
February 6, 2019
Stjepan Curic, Gregor Leicht, Stephanie Thiebes et al.
Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist, on the auditory-evoked...
Journal of Affective Disorders
February 1, 2019
Leorey N Saligan, Cristan A Farmer, Elizabeth D. Ballard et al.
Fatigue and depression are closely associated. The purpose of this secondary analysis was to understand the relationships between depression and improvements in specific depression domains on the anti-fatigue effects of ketamine, which we previously reported. This secondary analysis re-evaluated data collected longitudinally from 39 patients with treatment-resistant Major Depressive Disorder...